tiprankstipranks
Trending News
More News >
Kaken Pharmaceutical Co Ltd (JP:4521)
:4521

Kaken Pharmaceutical Co (4521) Price & Analysis

Compare
0 Followers

4521 Stock Chart & Stats

¥3712.00
-¥98.00(-2.16%)
At close: 4:00 PM EST
¥3712.00
-¥98.00(-2.16%)

Bulls Say, Bears Say

Bulls Say
Balance Sheet StrengthExtremely low leverage and a high equity ratio provide durable financial flexibility. This reduces refinancing and solvency risk, supports sustained R&D and manufacturing investment, and gives the company resilience to weather pricing revisions or cyclical dips without forcing asset sales or heavy borrowing.
High Sustained MarginsRobust gross and operating margins signal durable pricing power and efficient specialty-pharma economics. High margins create internal funding for clinical programs and commercialization, provide buffers against pricing pressure, and support long-term profitability even if top-line growth slows.
Strong Cash GenerationSolid operating cash conversion and a recent rise in free cash flow enhance self-funding ability for pipelines, capex, and shareholder returns. Reliable cash generation reduces dependency on external financing and strengthens long-term strategic optionality for partnerships or licensing.
Bears Say
Historical Revenue & Cash VolatilityMeaningful volatility in revenue and cash flow undermines medium-term predictability for R&D funding, manufacturing planning, and dividend or buyback policies. Persistent swings make budgeting harder, increase the chance of procyclical cost actions, and can constrain disciplined long-term execution.
Recent Declines In Reported GrowthSharp negative revenue and EPS growth indicate recent operational or demand setbacks that could reflect product life-cycle issues, one-off losses, or pricing/drug mix erosion. If persistent, such declines threaten sustainable earnings, limit reinvestment capacity, and pressure margins and strategic plans.
Concentration On Japan And NHI ExposureHeavy dependence on domestic sales and Japan's National Health Insurance pricing creates structural revenue risk from periodic NHI price revisions and reimbursement policy changes. Limited geographic diversification constrains growth upside and leaves results sensitive to regulatory pricing cycles.

4521 FAQ

What was Kaken Pharmaceutical Co Ltd’s price range in the past 12 months?
Kaken Pharmaceutical Co Ltd lowest stock price was ¥3540.00 and its highest was ¥4901.00 in the past 12 months.
    What is Kaken Pharmaceutical Co Ltd’s market cap?
    Kaken Pharmaceutical Co Ltd’s market cap is ¥152.18B.
      When is Kaken Pharmaceutical Co Ltd’s upcoming earnings report date?
      Kaken Pharmaceutical Co Ltd’s upcoming earnings report date is May 13, 2026 which is in 83 days.
        How were Kaken Pharmaceutical Co Ltd’s earnings last quarter?
        Kaken Pharmaceutical Co Ltd released its earnings results on Feb 06, 2026. The company reported ¥10.71 earnings per share for the quarter, missing the consensus estimate of ¥24.791 by -¥14.081.
          Is Kaken Pharmaceutical Co Ltd overvalued?
          According to Wall Street analysts Kaken Pharmaceutical Co Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Kaken Pharmaceutical Co Ltd pay dividends?
            Kaken Pharmaceutical Co Ltd pays a Semiannually dividend of ¥95 which represents an annual dividend yield of 4.16%. See more information on Kaken Pharmaceutical Co Ltd dividends here
              What is Kaken Pharmaceutical Co Ltd’s EPS estimate?
              Kaken Pharmaceutical Co Ltd’s EPS estimate is 47.07.
                How many shares outstanding does Kaken Pharmaceutical Co Ltd have?
                Kaken Pharmaceutical Co Ltd has 44,139,730 shares outstanding.
                  What happened to Kaken Pharmaceutical Co Ltd’s price movement after its last earnings report?
                  Kaken Pharmaceutical Co Ltd reported an EPS of ¥10.71 in its last earnings report, missing expectations of ¥24.791. Following the earnings report the stock price went down -0.121%.
                    Which hedge fund is a major shareholder of Kaken Pharmaceutical Co Ltd?
                    Currently, no hedge funds are holding shares in JP:4521
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Company Description

                      Kaken Pharmaceutical Co Ltd

                      Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

                      Kaken Pharmaceutical Co (4521) Earnings & Revenues

                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Kissei Pharmaceutical Co
                      Towa Pharmaceutical Co
                      Mochida Pharmaceutical Co., Ltd.
                      KYORIN Pharmaceutical Co.,Ltd.
                      SAWAI GROUP HOLDINGS Co., Ltd.

                      Options Prices

                      Currently, No data available
                      ---
                      Popular Stocks